Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer
- 1 December 1988
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 6 (4) , 323-325
- https://doi.org/10.1007/bf00173652
Abstract
Twenty-two patients with advanced colorectal cancer (CRC) (12 without prior chemotherapy) and fourteen with pretreated breast cancer (BC) were given mitozolomide (MTZ), IV infusion, every six weeks. The starting dose was 90 mg/m2. When it was well-tolerated, dose escalation was done up to 100–115 mg/m2. Toxicity was mild, limited to thrombocytopenia with a median nadir of 1.27 × 105 (0.20–4.86). No response was observed in these patients. MTZ, according to these schedule and dosage, does not show activity in human CRC and pretreated BC.Keywords
This publication has 3 references indexed in Scilit:
- PHASE-I CLINICAL-TRIAL OF MITOZOLOMIDE1985
- Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agentJournal of Medicinal Chemistry, 1984
- DNA CROSS-LINKING AND CYTO-TOXICITY IN NORMAL AND TRANSFORMED HUMAN-CELLS TREATED INVITRO WITH 8-CARBAMOYL-3-(2-CHLOROETHYL)IMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE1984